This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the ...
The recent rally in biotechnology stocks is being driven by improving fundamentals and a resurgence in merger activity rather than speculative excess, according to Jonathan Faison, founder of ROTY ...
CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group ...
Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the ...
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing ...
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
Another wave of layoffs has hit one of the Bay Area's biggest biotech companies—and the latest cuts push a troubling trend ...
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...
New York invests $65M in biotech with new clinical trial consortium and Biogenesis Park to compete with Boston, San Francisco ...
David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results